Image Analysis Group (IAG) at ASBMR 2026 — Boston

Bone is one of the few areas where imaging is not a surrogate for the disease but a direct measure of it, and ASBMR is where the methods for measuring it are debated and refined.

• Dates: 9–12 October 2026
• Time: 08:00–17:30 EDT (13:00–22:30 BST)
• Location: Boston Convention & Exhibition Center, Boston, Massachusetts, US

IAG’s musculoskeletal team can talk through the measurement questions that shape bone trials:

• DXA for bone mineral density, and the quality control needed to detect change reliably
• HR-pQCT for bone microarchitecture, and where it adds value beyond areal density
• Quantitative CT and finite element analysis in strength estimation
• Vertebral fracture assessment and reader agreement in fracture adjudication
• Endpoint selection in rare bone disease, where patient numbers are small and each measurement matters more
• Longitudinal scanner drift and cross-calibration across sites
• DYNAMIKA™, IAG’s imaging platform, and how automated analysis supports precision in bone measurement

• Clinical scientists and Medical Directors designing osteoporosis or rare bone disease trials
• Program leads selecting between DXA, HR-pQCT and quantitative CT
• Teams concerned about measurement precision across sites and scanner models
• Sponsors running small trials where every measurement carries weight

Christoph Salzlechner, Director, Quantitative Imaging and Imaging Biomarkers, covering musculoskeletal programs, will represent IAG at ASBMR 2026.

If you are designing a bone trial and want to talk through endpoint selection or measurement precision, get in touch to arrange a time in Boston. Christoph is happy to get into the detail.

To follow IAG’s work between events, including upcoming webinars on centralized imaging, AI-enabled endpoints and radiomics, follow us on LinkedIn.

Image Analysis Group (IAG) is a trusted partner to life sciences companies, combining deep expertise in medical imaging with the innovative power of its proprietary platform, DYNAMIKA™, to de-risk clinical development and accelerate the delivery of lifesaving therapies to patients.

The IAG team designs and executes the imaging part of clinical trials that rely on radiological endpoints to demonstrate the safety and efficacy of new drug candidates. By using AI-powered endpoints and automating data management processes, with IAG you accelerate start-up and database lock, gain real-time visibility on trial progress, ensure clean data for regulatory submissions, and maximize patient recruitment speed.

For nearly 20 years, IAG has supported more than 700 clinical trials globally, helping biotech and pharmaceutical sponsors make confident, data-driven decisions on their development portfolios.